Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency

• Author(s) / Creator(s)

  • Waye, Arianna
  • El Shayeb, Mohamed
  • Guo, Bing
  • Chuck, Anderson
  • Akpinar, Ilke
  • Chojecki, Dagmara
  • Yan, Charles
  • Corabian, Paula

• This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.

• Date created

  2016-03-23

• Subjects / Keywords

  • Blood spot screening
  • Newborn screening

• Type of Item

  Report

• DOI

  https://doi.org/10.7939/R3Z02ZP8Q

• License

  Attribution-NonCommercial-ShareAlike 4.0 International